Cisplatin, Paclitaxel, Tislelizumab | Molecular Oncology Almanac

Cisplatin, Paclitaxel, and Tislelizumab

Membership operator: AND

Therapies: 3

Cisplatin (tx:ncit:C376)

Paclitaxel (tx:ncit:C1411)

Tislelizumab (tx:ncit:C121775)

Precision oncology relationships for therapeutic response involving this therapy group.

Organizations

Biomarkers

Cancer types

Therapies

Organizations	Biomarkers	Cancer types	Therapies
EMA (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
FDA (2)	PD-L1 (TAP) >= 1%	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab
FDA (2)	PD-L1 (CPS) >= 1	Esophageal Squamous Cell Carcinoma	Cisplatin, Paclitaxel, Tislelizumab